"A drug-company whistle-blower last month pocketed $96 million -- her share of the money Medicare and Medicaid paid for tainted drugs. The fee is way too high -- employees will drop a dime for far less. And the FDA would do better to improve inspections rather than rely so heavily on whistle-blowers."